Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe, progressive central vision loss and is a leading ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy (GA ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular degeneration (nAMD) in eyes with geographic atrophy (GA) found that GA can ...

The results were published in The Lancet in October 2023. About SYFOVRE ® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy ...

announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from geographic atrophy (GA) secondary to ...